摘要
[目的]探讨AKT1的表达与卵巢浆液性肿瘤发生发展及卵巢癌化疗耐药的关系。[方法]免疫组织化学SP法检测67例卵巢浆液性腺癌(其中化疗耐药30例、化疗敏感37例)、10例卵巢交界性浆液性囊腺瘤、10例卵巢良性浆液性囊腺瘤和10例正常卵巢组织中的AKT1表达情况。[结果]AKT1的阳性表达率在卵巢浆液性腺癌、卵巢交界性浆液性囊腺瘤、卵巢良性浆液性囊腺瘤和正常卵巢组织中分别为62.69%、70.00%、40.00%和0,有显著统计学差异(P=0.001),在化疗耐药卵巢浆液性腺癌中明显高于化疗敏感者(P=0.033)。AKT1的阳性表达率在Ⅰ～Ⅱ期和Ⅲ～Ⅳ期卵巢浆液性腺癌中分别为31.58%和75.00%,有显著统计学差异(P=0.001)。AKT1的阳性表达率与卵巢浆液性腺癌患者绝经状态、组织学分级和淋巴结转移情况无关(P>0.05)。[结论]AKT1与卵巢浆液性肿瘤发生发展和卵巢癌化疗耐药有关,可作为预后和化疗耐药性的间接预测指标之一。
[Purpose] To investigate the relationship of AKT1 with occurrence and chemoresis- tance in ovarian serous neoplasms.[Methods] AKT1 expression in 67 cases with ovarian serous cystadenocarcinoma （30 cases, chemotherapy resistance; 37 cases, chemotherapy sensitivity）, 10 cases with ovarian borderline serous cystadenoma,10 cases with ovarian serous cystadenoma and 10 cases normal ovarian tissues were detected immonohistochemically. [Results] The posi- tive rates of AKT1 in ovarian serous cystadenocarcinoma,ovarian borderline serous cystadeno- ma, ovarian serous cystadenoma and normal ovarian tissues were 62.69%, 70.00% ,40.00% and 0 respectively,with significant difference （P=-0.001）. The positive rate of AKT1 in chemotherapy resistance ovarian serous cystadenocarcinoma was significantly higher than that in chemotherapy sensitive ovarian serous cystadenocarcinoma （P=0.033）. The positive rates of AKT1 in ovarian serous cystadenocarcinoma stage I -II and Ⅲ-Ⅳ were 31.58% and 75.00%,respectively,with significant difference （P=0.001）. The positive rate of AKT1 did not correlate with menopausal status, histological grade and lymph node metastasis（P〉0.05）. [Conclusion] AKT1 correlates with occurrence and ehemoresistance in ovarian serous cancer. It may be considered as a marker for predicting prognosis and chemoresistance.
出处
《肿瘤学杂志》
CAS
2013年第8期590-594,共5页
Journal of Chinese Oncology
基金
国家自然科学基金资助项目(30973189)
